Skip to Main Content

A European regulatory setback for a Bristol-Myers Squibb (BMY) blood-cancer drug could have a negative spillover effect for Agios Pharmaceuticals (AGIO) and its sole wholly owned drug.

On Friday, the European Medicines Agency disclosed that Bristol withdrew a marketing application for Idhifa, a targeted medicine to treat acute myeloid leukemia, after an ongoing review had concluded that the drug’s clinical data did not support approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!